Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

BACKGROUND: Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6. In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in combination with letrozole improved progression-free survival (PFS) compared with letrozole alone as first-line treatment of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Finn, Richard S., Crown, John P., Ettl, Johannes, Schmidt, Marcus, Bondarenko, Igor M., Lang, Istvan, Pinter, Tamas, Boer, Katalin, Patel, Ravindranath, Randolph, Sophia, Kim, Sindy T., Huang, Xin, Schnell, Patrick, Nadanaciva, Sashi, Bartlett, Cynthia Huang, Slamon, Dennis J.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924326/
https://ncbi.nlm.nih.gov/pubmed/27349747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-016-0721-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados